Belite Bio: The Oral Route Is The Real Competitive Moat
Belite Bio Inc BLTE
$158.61
▼ -0.82%
($-1.31)
🗓️ Earnings Next Week
Open
$159.63
Prev Close
$159.92
Day Range
$155.18 – $161.00
52W Range
$60.00 – $200.00
Market Cap
$6.41B
Beta
-1.20
EPS (TTM)
$-2.65
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-04-29 |
| Shares Out. | 40,090,000 |
| Website | belitebio.com/ ↗ |
| Phone | 18582466240 |
| Employees | 41 |
| Total Assets | $780.6M |
| Total Liabilities | $10.1M |
| Equity | $770.5M |
About Belite Bio Inc
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Belite Bio Inc is a publicly traded company under the ticker symbol BLTE on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)